SCHEMBL25551797

SCHEMBL25551797

Cc1ccc(-c2nc(Cl)ncc2Cl)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 2/20 0.42
▸ KCNQ2 O43526 2/20 0.42
▸ KCNE1 P15382 2/20 0.42
▸ KCNQ1 P51787 2/20 0.42
▸ KCNQ5 Q9NR82 1/20 0.42
▸ BTK Q06187 1/20 0.40
▸ KMO O15229 2/20 0.40
▸ NISCH Q9Y2I1 1/20 0.38
▸ CHRNA7 P36544 1/20 0.37
▸ PTGS2 P35354 1/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ RPS6KA5 O75582 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ CTSA P10619 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036996 1.00 KCNQ3 (0.42) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL30036275 0.88 KMO (0.40) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL25551800 0.88 KMO (0.40) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL25551795 0.83 KMO (0.59) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL30035839 0.83 KMO (0.59) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL12813119 0.78 AXL (0.49) KMONISCHCHRNA7PDK1PDK2
SCHEMBL30919676 0.78 BTK (0.43) BTKPDK1PDK2PDK4RPS6KA5
SCHEMBL31281284 0.78 CYP11B2 (0.53) —
SCHEMBL29340337 0.78 BTK (0.43) BTKKMOPDK1PDK2PDK3
SCHEMBL27263191 0.78 BTK (0.43) BTKPDK1PDK2PDK4RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-03-03 — — US disclosed
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed
EP-4110765-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE Board of Regents, The University of Texas System (US) 2023-01-04 — — EP disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 KCNQ3 4346/4885KCNQ2 4167/4885KCNE1 3965/4885
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease RIPK1, RIPK4, RIPK2 KCNQ3 3819/4885KCNQ2 3709/4885KCNE1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback